Опубликованные работы

2011

The impact of tumor-infiltrating natural killer cells on ovarian cancer progression. - (submitted) - El-Gazzar, A., Eckelhart, E., Perco, P., Horvat, R., Sexl, V., Krainer, M. (2011)

Silencing of N33 (TUSC3) Independently Predicts Ovarian Cancer Outcome by Modifying Cellular N-glycosylation Patterns - (submitted) - Pils, D., Petz, M., Alfanz, A., Gugerell, A., Wittinger, M., Gregor, W., Gleiss, A., Kirisits, A., Horak, P., Omann, M., Tong, D., Zeillinger, R., Braicu, El., Sehouli, J. and Krainer, M. (2011)

HCRP1 as Regulator of ERBB Receptor Trafficking is a Potential Biomarker for EGFR-Driven Tumors - (submitted) - Wittinger, M., El-Gazzar, A., Pils, D., Grunt, TW., Sibilia, M., Horvat, R., Schemper, M., Zeillinger, R., Schöfer, C. and Krainer, M. (2011)

Randomized, Double-Blind Study of  Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. - J Clin Oncol. - 29(9), 1125-1132. Henry, D.H., Costa, L., Goldwasser, F., Hirsh, V., Hungaria, V., Prausova, J., Scagliotti, G.V., Sleeboom, H., Spencer, A., Vadhan-Raj, S., von Moos, R., Willenbacher, W., Woll, P.J., Wang, J., Jiang, Q., Jun, S., Dansey, R., Yeh, H., and study group. (2011)

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resitant prostate cancer: a randomised, double-blind study. - Lancet - 377(9768):813-822. Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., Milecki, P., Shore, M., Rader, M., Wang, H., Jiang, Q., Tadros, S., Dansey, R., Goessl, C., and study group. (2011)

Recurrence Free Survival in Prostate Cancer is Related to Increased Stromal TRAIL Expression. - Cancer - 117(6):1172-82. Annes, M., Horak, P., El-Gazzar, A., Susani, M., Heinze, G., Perco, P., Pangerl, T., Loda, M., Lis, R., Krainer, M., and Oh, W.K. (2011)

2010

Assessment of a six gene panel for the molecular detection of circulatin tumor cells in the blood of female cancer patients. - BMC Cancer - 10.1186/1471-2407-10-666. Obermayer, E., Sanchez-Cabo, F., Muy-Kheng, T.M., Singer, C.F., Krainer, M., Fischer, M.B., Sehouli, J., Reinthaller, A., Horvat, R., Heinze, G., Tong, D., Zeillinger, R. (2010)

Natural immunity enhances the activiti of a DR5 agnostic antibody and carbopatin in the treatment of ovarian cancer.  - Mol Cancer Ther. - 9(4):1007-18. El-Gazzar, A., Perco, P., Eckelhart, E., Anees, M., Sexl, V., Mayer, B., Liu, Y., Mikulits, W., Horvat, R., Pangerl, T., Zheng, D., Krainer, M. (2010)

The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential. - Gynecol Oncol. - 117(3):451-9. El-Gazzar, A., Wittinger, M., Perco, P., Annes, M., Horvat, R., Mikulits, M., Grunt, T.W., Mayer, B., and Krainer, M. (2010)

BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-ß treatment. - Gynecol Oncol. - 117(2):189-97. Pils, D., Wittinger, M., Petz, M., Gugerell, A., Gregor, W., Alfanz, A., Horvat, R., Braicu, E.I., Sehouli, J., Zeillinger, R., Mikulits, W., and Krainer, M. (2010)

2009

Third consensus on medical treatment of metastatic breast cancer - Ann Onocol. - (11):1771-85. Beslija, S., Bonneterre, J., Burstein, H.J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, WJ., Krainer, M., Menard, S., Petit, T., Petrzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, CC., Zwierzina, H.; for the Central European Cooperative Oncology Group CECOG). (2009) 

2008

Chemotherapy for prostate cancer - Wien Klin Wochenschr. - 120(13-14):440-9. Rauchenwald, M., De Santis, M., Fink, E., Höltl, W., Kramer, G., Marei, IC., Neumann, HJ., Reissigl, A., Schmeller, N., Stackl, W., Hobisch, A., Krainer, M. (2008)

Linking the ovarian cancer transcriptome and immunome. - BMC Syst Biol. - 3;2:2. Rapberger, R., Perco, P., Sax, C., Pangerl, T., Siehs, C., Bernthaler, A., Lukas, A., Mayer, B., Krainer, M. (2008)

Targeting signaling pathways in ovarian cancer. - Expert Opinion on Therapeutic Targets - 12(3):353-365 Reibenwein, J., Krainer, M. (2008)

2007

Oncogenic BARD1 isoforms expressed in gynecological cancers. - Cancer Research - 67(24):11876-85. Li, L., Ryser, S., Dizin, E., Pils, D., Krainer, M., Jefford, Ch.E., Bertoni, F., Zeillinger, R., and Irminger-Finger, I. (2007)

EGFR Degradation and Cancer: Oncogenic Signalling from a different perspective. - Int J Biochem Cell Biol. - 39(12):2173-82. Kirisits, A., Pils, D., Krainer, M., (2007)

A Prospective, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly Vinorelbine as First Line Chemotherapy in Patients With Androgen Independent Prostate Cancer. - J Urol. - (Vol. 177, Issue 6, Pages 2141-2145). Krainer, M., Tomek, S., Elandt, K., Horak, P., Albrecht, W., Eisenmenger, M., Höltl, W., Schramek, P., Stackl, W., Zielinski, C., Reibenwein, J. (2007)

In ovarian cancer the prognostic influence of Her2/neu is independent from the CXCR4/SDF-1 signalling pathway. - Br J Cancer - 96(3):485-91. Pils, D., Pinter, A., Reibenwein, J., Alfanz, A., Horak, P., Schmid, B., Hefler, L., Horvat, R., Reinthaller, A., Zeillinger, R., Krainer, M. (2007)

Promoter Hyermethylation of GSTP1, AR, and 14-3-3σ in Serum of Prostate Cancer Patients and its clinical relevance. - The Prostate - 67(4):427-32. Reibenwein, J., Pils, D., Horak, P., Tomicek, B., Goldner, G., Worel, N., Elandt, K., Krainer, M. (2007)

The medical management of prostate cancer: a multidisciplinary team approach. - BJU Int. - 99(1):22-7. Sternberg, C., Krainer, M., Oh, W., Bracarda, S., Bellmunt, J., Ozen, H., Zlotta, A., Beer,T., Oudard, S., Rauchenwald, M., Skoneczna, I., Borner, M., Fitzpatrick, J. (2007)

2006

Second consensus on medical treatment of metastatic breast cancer. - Ann Oncol. - 18(2):215-225. Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Kostler, WJ., Krainer, M., Menard, S., Petit, T., Petruzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, C., Zwierzina, H. (2006)

2005

Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience. - Anticancer Drugs - 16(2):185-90. Kostler, WJ., Steger, GG., Krainer, M., Kornek, GV., Locker, GJ., Brodowicz, T., Marosi, C., Singer, CF., Hudelist, G., Rabitsch, W., Wiltschke, C., Zielinski, C. (2005)

Perturbation of the TRAIL cascade in ovarian cancer: Overexpression of FLIPL and deregulation of the functional TRAIL receptors DR4 and DR5. - Clinical Cancer Research - 11-8585-91. Horak, P., Pils, D., Pinter, A., Kaider, A., Elandt, K., Sax, C., Zielinski, C., Horvat, R., Zeillinger, R., Reinthaller, A., Krainer, M. (2005)

Five genes from chromosome 8p are significantly downregulated in ovarian cancer: N33 and EFA6R have a potential impact on overall survival. - Cancer - 104(11):2417-29. Pils, D., Horak, P., Gleiss, A., Sax, C., Fabjani, G., Möbus, V.J., Reinthaller, A., Zeillinger, R., Zielinski, C., Krainer, M. (2005)

Contribution of epigenetic silencing of TNF-related apoptosis inducing ligand (TRAIL) receptor 1 (DR4) to TRAIL resistance and ovarian cancer. - Molecular Cancer Research - (6):335-43. Horak, P., Pils, D., Haller, G., Pribill, I., Roessler, M., Tomek, S., Horvat, R., Zeillinger, R., Zielinski, C., Krainer, M. (2005)

Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. - Gynecologic Oncology - 97: 514-518. Horak, P., Pils, D., Roessler, M., Tomek, S., Elandt, K., Zeillinger, R., Zielinski, C., Krainer, M. (2005)

2004

Single agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: A single institution experience - Anticancer Drugs - 24 (2C): 1127-30. Köstler, W.J., Steger, G.G., Krainer, M., Kornek, G.V., Locker, G.J., Brodowicz, T., Marosi, C., Singer, C.F., Hudelist, G., Rabitsch, W., Wiltschke, C., Zielinski, C. (2004)

Resistance to Trail-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. - Gynecol Oncol - 94: 107-114. Tomek, S., Horak, P., Pribill, I., Haller, G., Rössler, M., Zielinski, C., Pils, D., Krainer, M. (2004)

Monitoring of Serum Her-2/neu Predicts Histopathologic Response to Neoadjuvant Trastuzumab-based Therapy for Breast Cancer. - Anticancer Research - 24: 1127-1130. Koestler, W.J., Steger, G.G., Soleiman, A., Schwab, B., Singer, C.F., Tomek, S., Brodowicz, T., Krainer, M., Wiltschke, C., Horvat, R., Jakesz, R., Zielinski, C. (2004)

Monitoring of Serum Her-2/neu predicts Response and Progression-free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer. - Clin Cancer Research - Clin Cancer Res - 10(5):1618-24 Koestler, W., Schwab, B., Singer, C., Neumann, R., Rücklinger, T., Brodowicz, T., Tomek, S., Niedermayr, M., Hejna, M., Steger, G.G., Krainer, M., Wiltschke, C., Zielinski, C. (2004)

2003

Cytotoxic Chemotherapy in Breast Cancer: Efficacy of Combination Therapy vs. Monotherapy. - Breast Cancer Res Tre - 81: 13-17. Krainer, M., (2003)

Consensus on medical treatment of breast cancer - Breast Cancer Res Tre - 81: 1-7. Krainer, M., and Zielinski, C. coordinators (2003)

Rad 52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients. - Oncol Rep - 10(5): 15551-3.
Tong, D., Volm, T., Eberhardt, E., Krainer, M., Leodolter, S., Kreienberg, R., Zeillinger, R. (2003)

Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. - Eur J Cancer -39(9): 1318-29.
Tomek, S., Koestler, W., Horak, P., Grunt, T., Brodowicz, T., Pribill, I., Halaschek, J., Haller, G., Wiltschke, C., Zielinski, C., Krainer, M. (2003)

2002

Technetium-99m-tetrofosmin scintigraphy in patients with metastatic soft tissue sarcoma. - Oncol Rep - 9, - 1009-13.
Karanikas, G., Koestler, W.J., Becherer, A., Wiesner, K., Dudczak, R., Krainer, M., Kletter, K. (2002)